Bharat Biotech, the maker of coronavirus disease vaccine Covaxin, is expected to start paediatric trials from June, the company’s Business Development and International Advocacy Head Dr Raches Ella on Sunday.
“We focused on developing the product last year. Now our focus is on ramping up our manufacturing capacity. Kids vaccine trials of Bharath Biotech may get the license in the third quarter of this year,” Dr Ella said during a virtual conversation with members of FICCI Ladies Organisation (FLO), Hyderabad.
Responding to a question from one of the participants, Dr Ella said that Bharat Biotech will be ramping up the manufacturing capacity of Covaxin to 700 million doses by the end of this year.
“We are happy to have the full support of the government because of which we are able to stand where we are today in this journey. The vaccine is co-developed by us and ICMR. The government placed an advanced purchase order of ₹1,500 crore. This will help us to increase our risk appetite. That is why we are expanding to Bangalore and Gujarat,” he added.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…